Artelis and Selexis Announce 31 g/L Yields in Multiple Perfusion Harvests
Artelis SA (Brussels, Belgium) and Selexis SA (Geneva, Switzerland) have announced manufacturing yields of more than 31 grams per liter in a CHO-based monoclonal antibody production process, in multiple harvests from a perfusion-like process.
Artelis and Selexis Announce 31 g/L Yields in Multiple Perfusion Harvests
Artelis SA (Brussels, Belgium) and Selexis SA (Geneva, Switzerland) have announced manufacturing yields of more than 31 grams per liter in a CHO-based monoclonal antibody production process, in multiple harvests from a perfusion-like process.
The high yields were achieved by applying a high-performance Selexis CHO production cell line and the iCELLis platform, a scalable, disposable, high-cell-density technology developed by scientists at Artelis.
The full program was concluded over about four months, starting with a high-performance cell line development at Selexis, followed by cell transfer and manufacturing at Artelis. The culture media used throughout the study was industry-standard cGMP grade and void of serum or any animal-derived components. Artelis and Selexis plan to expand the testing of the combined technologies by evaluating the iCELLis platform with Selexis-generated HEK293 cells lines.
iCELLis is a proprietary, single-use, technology developed by Artelis, designed to achieve and maintain high-cell densities on macrocarriers in a fixed-bed system. According to the company, these high-cell densities allow the compact iCELLis bioreactors to equal the productivity of much larger stirred-tank units.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
